Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.71

+0.4%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: seminole who wrote (1874)	10/24/2000 1:33:07 AM
From: Miljenko Zuanic	Read Replies (1) of 52153

<<However, the retirement of their Medical Director and resignation of their Chief Scientific Officer reported on Aug 17 has many thinking there is more than just a short delay here.>> First, Shrotriya has very limited experience in Oncology. Second, he first left MGI before become CSF at SUPG. Third he left SUPG (my guess is that he is kicked out) to become CMO at NEOT as neurologist (again bad choice for him and for NEOT). Bottom line, hi is joke. Regards the Prudential, I never count them seriously as Oncology house. More important, 9-NC PIII trials are most serious one for pancreatic cancer, as I have read about. For the record, I am giving more chance to 9-NC than Irofulven. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next